ASH 2021 | Novel therapeutic agents in the treatment of Hodgkin and non-Hodgkin Lymphoma
Ann LaCasce, MD, MMSc, Dana-Farber Cancer Institute, Boston, MA, highlights the educational importance and main goal of a continuing medical education (CME) session presented at this year’s ASH meeting, which aimed to bring new data about novel medicines to oncologists. Dr LaCasce outlines the format of this CME session, and then summarizes a variety of novel therapeutic agents available for the treatment of both Hodgkin and non-Hodgkin lymphoma, including chimeric antigen receptor T-cell (CAR-T) therapy, lenalidomide, tafasitamab, selinexor, and rituximab. To conclude, Dr LaCasce mentions that this session aimed to help clinicians receive more information and guidance when choosing the best treatment option for lymphoma patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
